Phase 3 roxadustat versus placebo for anemia in lower-risk myelodysplastic syndrome with low transfusion burden

Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) and anaemia comparing Roxadustat with Placebo (2 arms). Primary endpoint: Proportion of patients achieving transfusion independence for at least 56 consecutive days in the first 28 weeks of treatment. Started Jul 2017; status: terminated.